- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05674877
Opioid Sparing Anesthesia in Patients With Liver Cirrhosis Undergoing Liver Resection
Opioid Sparing Anesthesia in Patients With Liver Cirrhosis Undergoing Liver Resection: A Controlled Randomized Double Blind Study
Study Overview
Status
Conditions
Detailed Description
Patient enrollment will start after approval of the study protocol by the local Ethics and Research Committee and the Institutional Review Board (IRB) of the Departments of Anesthesia, ICU and Pain Management and the National Liver Institute, Faculty of Medicine, Menoufia University. The study will be conducted in the Anesthesia Department, National Liver Institute and will be registered with the ClinicalTrials.gov (http://www.clinicaltrials.gov) before patients enrollment.
The study will include adult patients with liver cirrhosis undergoing liver resection. Patients will be randomly allocated into one of the two study groups using an online randomization program (http://www.randomizer.org). Random allocation numbers will be concealed in opaque closed envelops. A written informed consent will be taken from each patient.
Five leads electrocardiography, pulse oximetry and peripheral perfusion index using masimo pulse oxymetry finger prope (Masimo, Irvine,CA, USA), end-tidal CO2, invasive arterial blood pressure, central venous pressure, The electrical cardiometry (EC) (ICON monitor; Cardiotronics Inc., La Jolla, CA, USA) for cardiac output monitoring (CO). oesophageal temperature, fraction inspired oxygen concentration, fraction inspired and expired desflurane. Bispectral index will be used to monitor the depth of anesthesia (BIS Covidien USA.), The neuromuscular function will be monitored using TOF-Watch SX (Schering-Plough, Swords, Co. Dublin, Ireland).
All patients fulfilling the study inclusion criteria will undergo a thorough clinical evaluation including laboratory assessment of liver and renal functions. Other diagnostic and/or laboratory workup will be requested by the attending anesthetist and the surgeon according to the patient clinical condition and the proposed surgical intervention.
Bilateral transversus abdominis plane (TAP) block:
All patients in the two study groups will receive a single shot ultrasound-guided bilateral TAP block using levopubivacaine. The effectiveness and dermatomal distribution of the block will be checked after 30 minutes and before induction of general anesthesia.
Anesthesia will be induced in all patients using fentanyl 2µg/kg, propofol 2 mg/kg, and rocuronium 0.6 mg/kg to facilitate endotracheal intubation. After induction of anesthesia, patients will be randomly allocated in two groups opioid sparing group (OS) and opioid-based group (OB). Patients in the Opioid Sparing group will receive a loading dose of dexmedetomidine (1µg/kg over 10 minutes). This will be followed by a fixed continuous maintenance infusion of 0.5µg/kg/hour. Furthermore, a single induction analgesic dose of 0.5 mg/kg ketamine will be given to all patients in the OS group. This will be followed by 0.25 mg/kg/h continuous maintenance infusion. Dexmedetomidine and ketamine infusions will be stopped 30 minutes prior to the conclusion of surgery. Patients in the opioid-based group will receive placebo boluses and infusions of saline. The attending anesthesiologist will be blinded to the patient group assignment.
Anesthesia will be maintained with a mixture of air, oxygen and desflurane to keep a BIS between 40 and 60. Muscle relaxation will be maintained by additional top-up doses of rocuronium 0.15mg/kg and will be guided by the response to ulnar nerve stimulation. Ventilation parameters will be adjusted to maintain normocapnia. Intraoperative normothermia will be maintained using a forced air warm blanket (Model 750-Bair Hugger Temperature Management Unit, SMA MISR, Arizant Healthcare Inc, USA), a humidifier, and warm intravenous fluids. Deep venous thrombosis (DVT) prophylaxis will include elastic stockings, sequential compression device (SCD) (Kendall Company, Tyco, USA) on the lower limb until early ambulation. Intraoperative fluid, fresh frozen plasma, and blood replacement therapy will be guided by the continuous monitoring of the central venous pressure and EC Cardiometry. and will be titrated to maintain hemodynamic stability and a hemoglobin level of 10 g/dL.
The intra-operative hemodynamics target will be to maintain the mean arterial blood pressure and heart rate within 20% of baseline value. Significant hemodynamic alterations will be managed as follows:
- Bradycardia (heart rate < 50 beats/min) will be managed by incremental 0.5 mg doses of atropine.
- Hypertension and/or tachycardia defined as more than 20% increase of the baseline readings will be managed by top-up doses of fentanyl 1µg/kg in the two study groups.
- Hypotension defined as more than 20% reduction in the baseline mean arterial blood pressure will be managed by incremental doses of ephedrine 5mg in the two study groups.
At the end of surgery and when two responses to train-of-four ulnar nerve stimulation are detected (T2), residual rocuronium-induced neuromuscular block will be antagonized by sugammadex 2 mg/kg. Patients will be discharged to the surgical intensive care unit after extubation. Postoperative analgesia will be achieved using patient-controlled fentanyl infusion (PCA fentanyl).
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Shibīn Al Kawm, Egypt
- National Liver Institute, Menoufia University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male and female patients with liver cirrhosis [Child A] aged 18 to 65 years undergoing liver resection.
- American Society of Anesthesiologists class II-III.
Exclusion Criteria:
- Renal or cardiac dysfunction
- History of chronic pain
- Alcohol or drug abuse
- Analgesic use in last 24 hours before surgery
- Major intraoperative hemodynamic instability
- The need for postoperative ventilation
- Psychiatric disorders
- Inability to comprehend pain assessment
- Allergy or contraindication to any of the study medications.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Opioid-based group (OB)
.Patients in the opioid-based group will receive placebo boluses and infusions of saline. The intra-operative hemodynamics target will be to maintain the mean arterial blood pressure and heart rate within 20% of baseline value. Significant hemodynamic alterations will be managed as follows: Hypertension and/or tachycardia defined as more than 20% increase of the baseline readings will be managed by top-up doses of fentanyl 1µg/kg |
Patients in the opioid-based group will receive placebo boluses and infusions of saline.
Other Names:
|
Active Comparator: Opioid sparing group (OS)
Patients in the Opioid Sparing group will receive a loading dose of dexmedetomidine (1µg/kg over 10 minutes). This will be followed by a fixed continuous maintenance infusion of 0.5µg/kg/hour. Furthermore, a single induction analgesic dose of 0.5 mg/kg ketamine will be given to all patients in the OS group. This will be followed by 0.25 mg/kg/h continuous maintenance infusion. Dexmedetomidine and ketamine infusions will be stopped 30 minutes prior to the conclusion of surgery. The intra-operative hemodynamics target will be to maintain the mean arterial blood pressure and heart rate within 20% of baseline value. Significant hemodynamic alterations will be managed as follows: Hypertension and/or tachycardia defined as more than 20% increase of the baseline readings will be managed by top-up doses of fentanyl 1µg/kg in the two study groups. |
Patients in the Opioid Sparing group will receive a dexmedetomidine (PRECEDEX™ "dexmedetomidine hydrochloride" - Pfizer) and ketamine.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intraoperative fentanyl requirements
Time Frame: Through operative time
|
Intraoperative fentanyl requirements in micrograms
|
Through operative time
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Postoperative PCA fentanyl requirements
Time Frame: Postoperative over 48 hours
|
Postoperative patient controlled analgesia (PCA) fentanyl requirements in micrograms
|
Postoperative over 48 hours
|
Incidence of severe postoperative opioid related adverse events
Time Frame: 48 hours after extubation
|
desaturation episodes (on room air), postoperative nausea and vomiting and postoperative ileus. Desaturation is defined as a decrease of oxygen saturation equal to or exceeding 4% of the baseline value. Postoperative ileus defined as absence of flatus or stools |
48 hours after extubation
|
Incidence of bradycardia
Time Frame: Through operative time
|
heart rate < 50 beats/min
|
Through operative time
|
Incidence of hypotension
Time Frame: Through operative time
|
Hypotension defined as more than 20% reduction in the baseline mean arterial blood pressure
|
Through operative time
|
Incidence of hypertension
Time Frame: Through operative time
|
Hypertension defined as more than 20% increase of the baseline readings
|
Through operative time
|
Extubation time
Time Frame: Time from antagonist administration till extubation
|
Time from antagonist administration till extubation
|
Time from antagonist administration till extubation
|
Postoperative pain score (VAS) score
Time Frame: 2 hours after extubation then every 6 hours for 48 hours
|
The Visual Analogue Scale (VAS) measures pain intensity.
The VAS consists of a 10cm line, with two end points representing 0 (no pain) and 10 (pain as bad as it could possibly be)
|
2 hours after extubation then every 6 hours for 48 hours
|
ICU and hospital length of stay
Time Frame: Immediate postoperative to maximum of 28 days
|
Defined as the number of days after extubation before first hospital discharge
|
Immediate postoperative to maximum of 28 days
|
Average required end-tidal desflurane
Time Frame: Through operative time
|
meaured in percentage
|
Through operative time
|
Surgical time
Time Frame: Through operative time
|
From skin incision to closure measured in minutes
|
Through operative time
|
Anesthesia time
Time Frame: Through operative time
|
From induction to extubation measured in minutes
|
Through operative time
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mohamed C Ollaek, Department of anesthesia, Surgical ICU and Pain Management
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Liver Diseases
- Fibrosis
- Liver Cirrhosis
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Dissociative
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Analgesics, Non-Narcotic
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Narcotics
- Hypnotics and Sedatives
- Ketamine
- Dexmedetomidine
- Analgesics, Opioid
Other Study ID Numbers
- 00309/2022
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liver Cirrhosis
-
Postgraduate Institute of Medical Education and...Society for the Study of Liver Diseases, Chandigarh ( India )UnknownDecompensated Cirrhosis of LiverIndia
-
The Second Affiliated Hospital of Chongqing Medical...RecruitingFibrosis, Liver | Cirrhosis, LiverChina
-
SUUMC Central Military Hospital Dr Carol DavilaRecruiting
-
The Cleveland ClinicRecruiting
-
The Cleveland ClinicRecruitingCirrhosis, LiverUnited States
-
University of PittsburghNational Institute on Drug Abuse (NIDA)CompletedCirrhosis, LiverUnited States
-
Beth Israel Deaconess Medical CenterAmerican Association for the Study of Liver Diseases FoundationCompleted
-
Asian Institute of Gastroenterology, IndiaCompletedCirrhosis, LiverIndia
-
Sherief Abd-ElsalamUnknown
Clinical Trials on Opioid-based group (OB) (placebo/saline)
-
Ege UniversityCompletedPsychological Stress | Psychology, Positive | Psychological Well-BeingTurkey
-
Dana-Farber Cancer InstituteNH TherAguix SASRecruitingMelanoma | Breast Cancer | Colorectal Cancer | Lung Cancer | Brain Cancer | Brain Tumor | HER2-positive Breast Cancer | Gastrointestinal Cancer | Brain Metastases | SRS | SRT | Whole Brain Radiation | Stereotactic Radiation | AGuIX | Nanoparticle | CysticUnited States
-
University Hospital, Basel, SwitzerlandRecruiting
-
Seoul National University HospitalCompletedRotator Cuff TearKorea, Republic of
-
University of FloridaOrtho Biotech Clinical Affairs, L.L.C.Completed
-
Second Affiliated Hospital of Wenzhou Medical UniversityRecruiting
-
Novartis VaccinesCompletedMeningococcal Disease | Meningococcal MeningitisKorea, Republic of
-
Weiqin LiJiangsu Province Hospital of Traditional Chinese Medicine; The First Affiliated... and other collaboratorsCompletedPancreatitis, Acute NecrotizingChina
-
University of AarhusAarhus University Hospital; Abbott; Meda PharmaceuticalsCompletedArthritis, RheumatoidDenmark